True Dose - Precision Dosing Technology
True Dose provides lab-quality at-home blood sampling technology for therapeutic drug monitoring, empowering pharma, healthcare, and research with precision dosing solutions.
About Us
Founded in 2023 as a spin-out from Karolinska Institutet in Stockholm, Sweden. Our research began in 2012 with the Tailordose project, led by Elham Hedayati, MD, PhD, and Per Rydberg, PhD.
Our Products
View all products: Product Catalog
Chemotherapy Monitoring
- TD-EPI - At-home blood sampling kit for Epirubicin level monitoring in breast cancer treatment. Download Product Sheet (PDF)
- TD-TAX - Kit for Docetaxel and Paclitaxel level monitoring in chemotherapy
Endocrine Therapy Monitoring
- TD-TAM/LET - Kit for Tamoxifen, Endoxifen, and Letrozole level monitoring in hormone receptor-positive breast cancer. Download Product Sheet (PDF)
Targeted Therapy Monitoring
- TD-CDK - Kit for CDK4/6 inhibitor level monitoring (Palbociclib, Ribociclib, Abemaciclib)
- TD-ALK - Kit for ALK inhibitor level monitoring in lung cancer treatment
Clinical Research
Instructions
Download Instructions For Use (PDF)
Key Benefits
- At-home capillary blood sampling
- Room-temperature stable samples
- Lab-quality precision
- Supports therapeutic drug monitoring (TDM)
- Enables personalized dosing strategies
Core Team
- Elham Hedayati, MD, PhD - Chief Medical Officer, Co-Founder. Associate Professor and Clinical Oncologist with over 20 years of experience. Co-founded True Dose to address challenges in patient recruitment for clinical trials due to complex blood sampling logistics.
- Azita Hedayati, MSc - CEO. Global commercial leader with Chemical Engineering background and Executive MBA. Dedicated to ensuring cancer patients benefit from precision care through innovative at-home sampling.
- Per Rydberg, PhD - Head of R&D, Co-Founder. PhD in Environmental Chemistry, driving force behind True Dose R&D. Co-founded True Dose to create devices that simplify therapeutic drug monitoring.
- Serena De Chiara, MSc - Development Manager. Chemist from Italy with extensive biotech experience, MSc in Medicinal Chemistry, specializing in mass spectrometry and analytical research.
- Nektarios Komninos, BSc - Senior Research Assistant. Background in Physics and Biomedicine, passionate about innovation in healthcare and improving patient outcomes through personalized medication.
- Djavad Hedayati - Chairman, Co-Founder. Former Partner at Netlight Consulting, Computer Science background. Co-founded True Dose after discovering only 45% of cancer patients receive correct medication doses.
- Hedvig Andersén - Advisory Board. Experience in capital raising, EU project financing, corporate finance, and venture capital investments. Served on boards of more than 20 companies.
Research & Publications
True Dose is a spin-out from Karolinska Institutet, bringing pioneering research in therapeutic drug monitoring (TDM) and precision medicine into clinical use. View all research: Research Page
Peer-Reviewed Publications (2025)
- Usability Study: Crafoord, M.-T., Hedayati, E., & Johnsson, A. (2025). "Capillary blood self-sampling for therapeutic drug monitoring: A mixed-methods usability study of the True Dose® kit." BioMed Research International, 2025, Article 9973081. DOI: 10.1155/bmri/9973081
- Analytical Validation: Komninos, N., De Chiara, S., Checa, A., Wiklander, O., Rydberg, P., & Hedayati, E. (2025). "Development and evaluation of a novel capillary blood collection method for decentralized therapeutic drug monitoring using the True Dose® kit." Scientific Reports, 15, Article 33331. DOI: 10.1038/s41598-025-20951-5
Ongoing Clinical Studies
- TailorDose II Trial (EUCT: 2024-514818-12-00) - Validation trial at Karolinska University Hospital evaluating True Dose® kits for decentralized TDM in early-stage breast cancer
- Abemaciclib Pharmacokinetics Study - Multicenter study in Sweden investigating exposure-toxicity relationships in hormone receptor-positive breast cancer
- Decentralized TDM in NSCLC - Planned study evaluating at-home sampling feasibility for lung cancer patients on taxanes or ALK inhibitors
Contact
Visit truedose.com for more information.